Beta-adrenergic receptor blocking drugs in angina pectoris.
D000319:Adrenergic beta-Antagonists / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D000526:Alprenolol / Q000627:therapeutic use; D000787:Angina Pectoris / Q000188:drug therapy* / Q000503:physiopathology; D001794:Blood Pressure / Q000187:drug effects; D004305:Dose-Response Relationship, Drug; D004341:Drug Evaluation; D004983:Ethanolamines / Q000627:therapeutic use; D005080:Exercise Test; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D010096:Oxprenolol / Q000627:therapeutic use; D010101:Oxygen Consumption / Q000187:drug effects; D005082:Physical Exertion; D010869:Pindolol / Q000627:therapeutic use; D011217:Practolol / Q000627:therapeutic use; D011433:Propranolol / Q000627:therapeutic use; D013015:Sotalol / Q000627:therapeutic use
D000319:Adrenergic beta-Antagonists; D004983:Ethanolamines; D010096:Oxprenolol; D000526:Alprenolol; D011433:Propranolol; D013015:Sotalol; D010869:Pindolol; D011217:Practolol